Skip to main content

Table 1 Neurologic immune-related adverse events reported with ICIs versus those reported in the full database from VigiBase, from Nov 14, 1967, to September 28, 2018

From: Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

 

Overall ICIs

Full database (starting 1967)

IC / IC025

Total number of ICSRs available

48,653

18,518,994

 

Number of ICSRs by irAE subgroups

Neuromuscular junction dysfunction (myasthenia gravis)

228 (0.47%)

7455 (0.04%)

3.51/3.31

Noninfectious encephalitis and/or myelitis

250 (0.51%)

9267 (0.05%)

3.33/3.15

Cerebral artery vasculitis

34 (0.07%)

1206 (0.01%)

3.23/2.71

Peripheral neuropathy

564 (1.16%)

123,463 (0.67%)

0.80/0.68

 - Guillain-Barre syndrome

122 (0.25%)

9508 (0.05%)

2.27/2.00

 - Chronic polyneuropathies

23 (0.05%)

6428 (0.03%)

0.43/−0.22

 - Mononeuropathies

42 (0.09%)

17,075 (0.09%)

−0.09/− 0.58

Noninfectious meningitis

72 (0.15%)

10,532 (0.06%)

1.36/1.01

Hemorrhagic central nervous system vascular conditions

386 (0.79%)

195,577 (1.06%)

−0.41/− 0.56

Cranial nerve disorders (excluding neoplasms)

226 (0.46%)

112,639 (0.61%)

−0.39/− 0.58

Cerebral ischemia

332 (0.68%)

174,768 (0.94%)

−0.47/− 0.63

Spinal cord and nerve root disorders

27 (0.06%)

11,875 (0.06%)

−0.21/− 0.80

Speech and language abnormalities

215 (0.44%)

125,871 (%)

−0.62/− 0.82

Seizures

291 (0.60%)

238,924 (0.68%)

−1.11/−1.28

Headaches

776 (1.59%)

731,460 (3.95%)

−1.31/− 1.41

Coma states

56 (0.12%)

43,228 (0.23%)

−1.01/− 1.41

Extrapyramidal syndrome

854 (1.76%)

840,831 (4.54%)

−1.37/− 1.47

Sensory abnormalities

520 (1.07%)

551,559 (2.98%)

−1.48/− 1.60

Dementia

21 (0.04%)

15,706 (0.08%)

−0.96/−1.64

Movement disorders

396 (0.81%)

427,006 (2.31%)

−1.50/− 1.65

Vertigos

89 (0.18%)

91,034 (0.49%)

−1.42/− 1.74

Nervous system neoplasms benign

5 (0.01%)

2302 (0.01%)

−0.25/−1.78

Sleep disturbances

239 (0.49%)

314,528 (1.70%)

−1.79/− 1.98

Psychosis and psychotic disorders

183 (0.38%)

284,048 (1.53%)

−2.03/−2.24

Demyelinating disorders

38 (0.08%)

87,190 (0.47%)

−2.58/−3.07

  1. Data are N (%) unless otherwise stated. ICIs refers to any ICSRs reported for treatment with nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, ipilimumab, or tremelimumab. A positive IC025 value (> 0) is the traditional threshold used in statistical signal detection with VigiBase. ICSRs individual case safety reports. ICIs immune checkpoint inhibitors. IC information component. IC025 = lower end of a 95% credibility interval for the IC
  2. Bold text denotes statistically significant differences